Phosphorous Magnetic Resonance Spectroscopy of Heart

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2014 by Washington University School of Medicine
Sponsor:
Information provided by (Responsible Party):
Adil Bashir, Washington University School of Medicine
ClinicalTrials.gov Identifier:
NCT01110395
First received: April 22, 2010
Last updated: February 18, 2014
Last verified: February 2014
  Purpose

Heart needs constant supply of energy to continue working. Phosphorus magnetic resonance spectroscopy allows us to measure energy produced in the heart. The purpose of this study is to determine if the energy production is reduced in failing heart.


Condition
Left Ventricular Dysfunction

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: 31P Magnetic Resonance Spectroscopy of Heart

Further study details as provided by Washington University School of Medicine:

Primary Outcome Measures:
  • A MR spectroscopy technique to measure creatine kinase flux in the heart is being developed [ Time Frame: three years ] [ Designated as safety issue: No ]

Estimated Enrollment: 15
Study Start Date: June 2009
Estimated Study Completion Date: June 2015
Estimated Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
Groups/Cohorts
Heart Failure
Magnetic Resonance Spectroscopy

Detailed Description:

We will use non-invasive phosphorus magnetic resonance spectroscopy technique to measure creatine kinase (CK) flux in failing heart. The studies will be done on Siemens 3.0T human system. We will recruit subjects with LV dysfunction due to prior anterior wall myocardial infarction.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

The study population will be individuals with left ventricular dysfunction including men and women of all races.

Criteria

Inclusion Criteria:

  • Individuals with left ventricular dysfunction

Exclusion Criteria:

  • Age < 18, pregnant, history of excessive alcohol use, or any condition (e.g. claustrophobia, a pacemaker) that would prevent him/her from completing the magnetic resonance spectroscopy study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01110395

Contacts
Contact: Adil Bashir 314-362-7403
Contact: Kitty Krupp, RN 314-747-0183 kruppk@mir.wustl.edu

Locations
United States, Missouri
Washington University in St. Louis Active, not recruiting
St. Louis, Missouri, United States, 63110
Washington University in St. Louis Recruiting
St. Louis, Missouri, United States, 63110
Contact: Adil Bashir, PhD    314-362-7403    bashira@mir.wustl.edu   
Sponsors and Collaborators
Washington University School of Medicine
Investigators
Principal Investigator: Adil Bashir, PhD Washington University School of Medicine
  More Information

No publications provided

Responsible Party: Adil Bashir, Research Instructor in Radiology, Washington University School of Medicine
ClinicalTrials.gov Identifier: NCT01110395     History of Changes
Other Study ID Numbers: 09-0533
Study First Received: April 22, 2010
Last Updated: February 18, 2014
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Ventricular Dysfunction, Left
Ventricular Dysfunction
Heart Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on August 26, 2014